These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical value of drugs targeting inflammation for the management of coronary artery disease. Duchatelle V; Kritikou EA; Tardif JC Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034 [TBL] [Abstract][Full Text] [Related]
26. Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model. Bai W; Zheng X; Zhou L; Li H Can J Physiol Pharmacol; 2012 Feb; 90(2):131-9. PubMed ID: 22309388 [TBL] [Abstract][Full Text] [Related]
27. Pleiotropic effects of statins in atherosclerosis and diabetes. Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
29. [Statins with a perspective of lifelong therapy]. Ertaş FS Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048 [TBL] [Abstract][Full Text] [Related]
33. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week. Nelson K; Fuster V; Ridker PM J Am Coll Cardiol; 2023 Aug; 82(7):648-660. PubMed ID: 37558377 [TBL] [Abstract][Full Text] [Related]
34. The role of aspirin, statins, colchicine, and IL-1 inhibitors in prevention of cardiovascular events: a systematic integrative review. Arboleda V; Hackworth A; Bonnice S; Gonzalez V; Cabrera D; Colletti C; Baxter C; Aleman Oliva C; Kabir S; Huang J; Khan A; Filoramo S; Ecoff S; Demory Beckler M; Kesselman MM J Osteopath Med; 2024 Mar; 124(3):97-106. PubMed ID: 37877246 [TBL] [Abstract][Full Text] [Related]
35. [Statins in the management of dyslipidemias]. Scheen AJ Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981 [TBL] [Abstract][Full Text] [Related]
36. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Patrick L; Uzick M Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071 [TBL] [Abstract][Full Text] [Related]
38. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol. Tani S; Nagao K; Hirayama A Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320 [TBL] [Abstract][Full Text] [Related]
39. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Lardizabal JA; Deedwania P Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102 [TBL] [Abstract][Full Text] [Related]
40. Statins and stroke prevention. Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]